Friday, September 30, 2022


Biotechnology News Magazine

BioInnovation Institute Announces Latest Cohort of Companies Entering Venture Lab Program

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating world-class life science research, today announces the latest cohort of participants in its Venture Labacceleration program for early-stage companies.

BioInnovation Institute notes the eight ventures are strategically aligned with BII’s focus, developing ground-breaking scientific initiatives across three specialist areas – therapeutics, bioindustrials and health tech.

Designed to help build research-based ideas with high-growth commercial potential into viable start-ups, BII’s 12-month Venture Lab program supports business acceleration, scientific and team development, and provides a risk-free convertible loan of EUR 0.5 million plus access to labs and offices at BII’s entrepreneurial ecosystem in the center of Copenhagen.  Since inception in 2018, BII has supported 71 start-ups and projects with EUR 44 million in funding.

Commenting on today’s launch, Bobby Soni, Chief Business Officer at BioInnovation Institute, said: “Following the launch of our Venture Lab program last year and an initial intake of exciting new companies, BII has continued to receive a stream of promising applications. We are delighted to announce the next cohort of start-up initiatives accepted onto the program and we look forward to supporting them with the many aspects of development needed to deliver first-in-class science that will positively impact global health and the environment.”

The new ventures BII has accepted into the Venture Lab program are:

  • Ousia Pharma: Danish biotech start-up focused on the design and development of effective and safe pharmacotherapies to improve the health and lives of the >650 million people living with obesity.
  • Tetrakit Technologies: developing the next generation of radioactive drugs to find and destroy cancer tumors. Tetrakit Technologies’ mission is to enable better, safer and more cost-effective theranostic radiopharmaceuticals for patients with advanced cancer.
  • Nordic Virtual Pastures: aims to accelerate the cultured meat revolution through a ground-breaking new method. The Company’s cultured minced beef product, ‘Poetic Meat’, will allow the world to continue eating meat without the environmental and ethical issues that surround the conventional meat industry.
  • Algiecel: uses natural micro-algae organisms, a highly compact and high yield photobioreactor technology fitted into standard shipping containers and a new revenue sharing business model to offer carbon capture as a service to industrial clients.
  • Aiomic: developing the Surgical Advanced Warning (SAW) system to combat postoperative complications. With automated tracking and real-time risk assessment, the SAW system will function as a business intelligence tool for hospitals, a decision support tool for healthcare practitioners and an individualized patient empowerment tool for surgical candidates.
  • Mello: developing a unique and technologically advanced encapsulation delivery system, suitable for preserving sensitive ingredients such as probiotics, live-biotherapeutics and bio-actives. Our solution will optimise the potential for therapeutic and health conferring effectiveness, via food and drink, by enhancing (ingredient) integrity, during processing, storage and downstream transfer.
  • Warburg Oncology: working on novel and innovative therapeutic principles focused on inhibition of tumour-cell metabolism and immune-evasion.
  • Probmet: a precision oncology therapeutics company developing targeted treatments for breast cancer brain metastatic patients. Scientists and clinicians will lead the development of breakthrough targeted therapies for metastatic breast cancer in the brain, a devastating disease that currently has limited treatment options.

Each start-up will be supported in undertaking the necessary steps to reach initial proof-of-concept, to make a business plan and to set up a team. Assisted by a dedicated scientific advisor, a leadership coach and a BII business development expert, these new ventures will be guided in developing a detailed milestone plan and will be provided assistance in overcoming the challenges of growing a business.

BII’s start-ups have in total raised more than EUR 147 million from local and international investors. Its diverse team brings venture capital, pharma and business expertise together to help early-stage companies accelerate to the next stage of growth. Recent company successes include Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Chromologics.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine